Compare MGM Resorts International (MGM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Stryker Corporation — how do they compare? MGM Resorts International trades at $29.27 (market cap $7.55B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 14.1× MGM Resorts International's market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Stryker Corporation for 21 Days on average.
| MGM | SYK | |
|---|---|---|
Market Cap | $7.55B | $106.24B |
Volume | 5,342,346 | 2,982,001 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $388.35 |
52-Week Low | $30.00 | $269.75 |
Typical Hold Time | 91 Days | 21 Days |
Enterprise Value | $34.85B | $117.70B |
Dividend Yield | 0.03% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement (+0.03%) amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock faces bearish technical signals with oversold RSI readings, while fundamentals show mixed results with Q2 2026 earnings beating expectations but net margins declining to 2.4% in 2025. Recent news highlights potential MGM interest in acquiring People Inc., creating uncertainty around strategic direction.
MGM presents a value opportunity with P/S ratio of 0.45 below industry averages, supported by strong analyst consensus ($48.75 price target, 51% buy ratings). However, risks include declining profit margins, failed acquisition attempts, and ongoing debt burden. The stock's current discount to analyst targets suggests potential upside if operational improvements materialize.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
